

<b>Product Name</b>	: EC5026
<b>Synonyms</b>	: BPN-19186
<b>Cat No.</b>	: M22930
<b>CAS Number</b>	: 1809885-32-2
<b>Molecular Formula</b>	: C <sub>18</sub> H <sub>23</sub> F <sub>4</sub> N <sub>3</sub> O <sub>3</sub>
<b>Formula Weight</b>	: 405.39
<b>Chemical Name</b>	: —
<b>Description</b>	<p>EC5026 has the potential to relieve pain by stabilizing natural analgesic and anti-inflammatory mediators. EC5026 (BPN-19186) is a first-in-class, small molecule that potently inhibits soluble Epoxide Hydrolase (sEH), a key regulatory enzyme involved in the metabolism of membrane fatty acids. Inhibition of sEH treats pain by stabilizing natural analgesic and anti-inflammatory mediators. sEH inhibitors developed by EicOsis have already shown efficacy for treating pain with no apparent adverse or addictive effects in laboratory animals and relieving naturally occurring pain in dogs, cats and horses.</p>
<b>Pathway</b>	: Others
<b>Target</b>	: Other Targets
<b>Receptor</b>	: sEH
<b>Solubility</b>	: DMSO:250 mg/mL (616.69 mM)
<b>SMILES</b>	: <chem>O=C(NC1CCN(C([C@@H](C)CC)=O)CC1)NC2=CC=C(OC(F)(F)F)C(F)=C2</chem>
<b>Storage</b>	: (-20°C)
<b>Stability</b>	: ≥ 2 years
<b>Reference</b>	:

1. EicOsis Announces FDA Acceptance of IND Application for EC5026, the First Soluble Epoxide Hydrolase Inhibitor to Treat Pain.2019.